ASSENT 4

ASSENT 4

Assessment of the Safety & Efficacy of a New Treatment Strategy for Acute Myocardial Infarction. An ongoing trial assessing a bolus thrombolytic (Metalyse®/TNKase™ tenecteplase + PCI, aka primary angioplasty) for treating acute myocardial infarction.
References in periodicals archive ?
The 4,000-patient trial, ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction) has two arms: half the patients enrolled will receive a drug regimen consisting of a full-dose, single bolus of TNKase(TM)/Metalyse(R) plus unfractionated heparin followed by immediate PCI.
The primary endpoint of ASSENT 4 PCI is a composite of death or cardiogenic shock or congestive heart failure within 90 days.
Frans Van de Werf, University Hospital Gasthuisberg, Leuven, Belgium, and chairman of the ASSENT 4 PCI trial.
In ASSENT 4 PCI, we are examining whether AMI patients facing a delay prior to PCI may be better served by receiving a bolus thrombolytic plus heparin, which can be given immediately, followed by PCI when it becomes possible," said Dr.